D-Fi

Phase 3Biologic

CCastle Creek Biosciences, LLC.

D-Fi is one of 41 biologic programs targeting Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TreatmentActive, not recruiting

TreatmentPhase 3

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

D-Fi

CCastle Creek Biosciences, LLC.

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Alfenta

Jazz Pharmaceuticals

Preclinical

1 4

Niclocide

Bayer

Preclinical

1 5

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 6

Valium

Akero Therapeutics

Preclinical

2 7

Clomid

Ferring

Preclinical

1 8

Aurlumyn

BBTG International Inc.

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2042

Phase 3Active, not recruiting

Treatment

NCT06892639

Clinical

Trials by Indication[1]

Treatment1 trial

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

Active, not recruiting·CCastle Creek Biosciences, LLC.·Phase 3·NCT06892639·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for D-Fi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-Fi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-Fi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Castle Creek Biosciences, LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCastle Creek Biosciences, LLC.

D-Fi

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2042

Trials by Indication[1]

Treatment1 trial

References

Drug Info

Quick Facts

Related News